Sangamo engaged with the FDA on alternative pathways to potential approval following analysis of clinical data from the Phase 1/2 STAAR study ... to our lack of capital resources to obtain ...

Sangamo engaged with the FDA on alternative pathways to potential approval following analysis of clinical data from the Phase 1/2 STAAR study showing encouraging ... related to our lack of capital ...

Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings ... to the $8 million or 10% increase in ICL sales and $0.2 million decrease in other products. Constant currency net ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...

Six analysts surveyed by Zacks expected $87.2 million. Staar Surgical expects full-year revenue in the range of $340 million to $345 million. This story was generated by Automated Insights (http ...

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding ...

For two years, experts from D.C. to Silicon Valley warned that rapid advances in the technology would turbocharge ...

Please verify your email address. A fan created a comical alternate introduction to Silent Hill 2 Remake, featuring skateboarding and a dance-off. The animation diverges from the game's usual dark ...

alt sponsors and speaks at Human Resource Agent Summit 2024: Agent Survival hosted by BungeishunjuーDecline or Rebirth? The Dawn of the“Warring Agents Period” Brought About by Generative AI ...

The researchers found that the 32 participants lost an average of 5.2 kg over a 12-week period. Although alternate-day fasting may be helpful for promoting weight loss, another 2016 study ...